We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

244 hedge funds and large institutions have $3.12B invested in Axsome Therapeutics in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 70 increasing their positions, 88 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more call options, than puts

Call options by funds: $79.2M | Put options by funds: $41.4M

83% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 24

30% more funds holding in top 10

Funds holding in top 10: 10 → 13 (+3)

18% more capital invested

Capital invested by funds: $2.65B → $3.12B (+$473M)

8% more funds holding

Funds holding: 226 → 244 (+18)

2.6% more ownership

Funds ownership: 80.28% → 82.88% (+2.6%)

20% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 88

Holders
244
Holders Change
+18
Holders Change %
+7.96%
% of All Funds
3.56%
Holding in Top 10
13
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+30%
% of All Funds
0.19%
New
44
Increased
70
Reduced
88
Closed
24
Calls
$79.2M
Puts
$41.4M
Net Calls
+$37.9M
Net Calls Change
+$18.3M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$62.9M
2
PA
Perceptive Advisors
New York
+$37.2M
3
Millennium Management
Millennium Management
New York
+$27.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$20.4M
5
BlackRock
BlackRock
New York
+$20.4M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$65.3M
2
NIP
Nicholas Investment Partners
California
-$20.9M
3
SCM
Soleus Capital Management
Connecticut
-$16.6M
4
Citadel Advisors
Citadel Advisors
Florida
-$13.8M
5
BI
BVF Inc
California
-$10M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
26
Eventide Asset Management
Massachusetts
$27.6M – – –
Northern Trust
27
Northern Trust
Illinois
$27.3M -$384K -5,749 -2%
TCM
28
Tang Capital Management
California
$25.5M – – –
Charles Schwab
29
Charles Schwab
California
$23.5M +$390K +5,830 +2%
FTM
30
First Turn Management
California
$23.5M +$19.8M +295,428 New
DCM
31
Driehaus Capital Management
Illinois
$21.2M +$1.13M +16,953 +7%
Wellington Management Group
32
Wellington Management Group
Massachusetts
$19.1M +$151K +2,265 +1%
N
33
Nuveen
North Carolina
$18.7M +$1.21M +18,089 +8%
Goldman Sachs
34
Goldman Sachs
New York
$16.4M +$3.11M +46,566 +29%
Norges Bank
35
Norges Bank
Norway
$15.5M -$1.01M -15,099 -7%
Barclays
36
Barclays
United Kingdom
$15.3M +$11.7M +175,052 +1,041%
JP Morgan Chase
37
JP Morgan Chase
New York
$15.1M +$1.17M +17,449 +10%
Bank of America
38
Bank of America
North Carolina
$14M +$9.3M +139,041 +375%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$13.2M -$115K -1,713 -1%
GTC
40
Ghost Tree Capital
New York
$13.1M +$3.68M +55,000 +50%
CC
41
Checkpoint Capital
California
$12.4M +$10.4M +155,346 New
T. Rowe Price Associates
42
T. Rowe Price Associates
Maryland
$11.7M +$8.29M +123,949 +548%
US Bancorp
43
US Bancorp
Minnesota
$11.4M +$311K +4,653 +3%
IAM
44
Iridian Asset Management
Connecticut
$11M -$448K -6,696 -5%
ACM
45
Altium Capital Management
New York
$11M +$3.08M +46,000 +50%
TLP
46
Tri Locum Partners
New York
$10.4M -$787K -11,772 -8%
SSA
47
Schonfeld Strategic Advisors
New York
$8.5M +$2.62M +39,144 +58%
WCM Investment Management
48
WCM Investment Management
California
$8.34M +$591K +8,845 +9%
Citigroup
49
Citigroup
New York
$8.1M -$62.5K -935 -0.9%
ABG
50
Ally Bridge Group
New York
$8.03M -$651K -9,738 -9%
1
2
3 4 5

AXSM Hedge Fund Activity: Q4 2023 in Review

244 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2023, worth a combined $3.12B — up 18% from $2.65B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new AXSM positions and 24 closed out — a net gain of 20 holders — while 70 added to existing stakes and 88 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $62.9M. The largest seller was Fidelity Investments, cutting an estimated $65.3M.

  • 244 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2023, up from 226 in Q3 2023.
  • Funds reported $3.12B of Axsome Therapeutics stock for Q4 2023, up 18% quarter-over-quarter.
  • 44 funds opened new Axsome Therapeutics positions in Q4 2023 and 24 closed out, a net change of +20 holders.
  • The largest Axsome Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $62.9M added.
  • The largest Axsome Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $65.3M sold.

Based on aggregated 13F filings for Q4 2023.